Tiervlei Trial Centre

Cape Town, Western Cape 7531

1 studies enrolling now · 14 studies all time

What they study most

COVID-19, Cardiovascular Disease, Cardiovascular Risk, Chronic Heart Failure With Preserved Ejection Fraction, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Dyslipidemia, Heart Failure, Inflammation, Influenza, Influenza, Human, Non-alcoholic Steatohepatitis

Studies at this site

• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) — Running, not enrolling
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease — Completed
• Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients — Completed
• Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza — Completed